Princeton 4:

PDE-5 Inhibitors and

Cardiac Health Symposium

Friday, March 10th, 2023.

Huntington Medical Research Institutes, 686 S. Fair Oaks Ave., Pasadena, CA 91105

This is a scientific expert panel supported by an unrestricted research grant by Sanofi.

Join us for: Princeton 4, bringing together the brightest specialists in a variety of healthcare fields to share the newest research on the interaction between sexual health and the heart! Space is limited so register EARLY!

About the Event


Friday, March 10, 2023 of the symposium will include didactic lectures and panel discussions from thought leaders and leading scientists who have actively contributed to the field in the intervening decade. We invite health care providers, researchers, trainees, journal editors, as well as representatives of industry and government concerned with promotion and regulation of PDE-5 inhibitors to register to attend in the Registration Tab.


Friday, March 10th, 2023

Symposium Location: Huntington Medical Research Institutes, 686 S. Fair Oaks Ave., Pasadena, CA 91105

Timing (Pacific) Agenda Speaker
8:00 AM - 8:25 AM Coffee and Continental Breakfast
8:35 AM - 8:40 AM Introduction and Welcome Julia Bradsher PhD, MBA
Robert A. Kloner MD, PhD
Raymond Rosen PhD
8:40 AM - 8:45 AM Meeting Overview and Purpose Robert A. Kloner MD, PhD
Raymond Rosen PhD
Section on ED: The Workup in 2023 Moderator:
Robert A. Kloner MD, PhD
8:45 AM - 9:00 AM “Work-up for ED in 2023. Is the Princeton 3 algorithm still correct, and what is the role of telemedicine?” Martin Miner MD
9:00 AM - 9:15 AM “Is ED an independent risk factor or risk marker for cardiovascular disease and what is the role of CT Calcium Scoring?” Michael Blaha MD, MPH
9:15 AM - 9:30 AM “Work- up of young men with ED. Do younger men with ED have greater risk of cardiovascular and all- cause mortality?” Tobias Kohler MD, MPH
9:30 AM - 9:45 AM “Update on psychologic impact of ED and impact of treating ED.” Raymond Rosen PhD
9:45 AM - 10:15 AM PANEL 1 Moderators:
Robert A. Kloner MD, PhD
Hossein Sadeghi-Nejad, MD
Martin Miner MD
Michael Blaha MD, MPH
Tobias Kohler MD, MPH
Raymond Rosen PhD
... More
10:15 AM - 10:35 AM COFFEE BREAK
Section on Therapy for ED: Focus on PDE 5 inhibitors Moderator:
Raymond Rosen PhD
10:35 AM - 10:50 AM “Update on PDE-5 inhibitors. Safety, new PDE-5 inhibitors, over- the-counter PDE-5 inhibitors?” Kevin McVary MD
10:50 AM - 11:05 AM “Nutritional supplements and the safety issues around adding PDE-5 inhibitors to dietary supplements.” Ira Sharlip MD
11:05 AM - 11:20 AM “Recent studies on safety of PDE-5 inhibitors with antihypertensive medicines and nitrates. Should nitrates remain a contraindication or now be considered a warning?” Peter Ganz MD
11:20 AM - 11:50 AM PANEL 2 Moderators:
Raymond Rosen PhD
Richard Sadovsky MD
Mark Hirsch MD
Kevin McVary MD
Ira Sharlip MD
Peter Ganz MD
11:50 AM - 1:05 PM LUNCH BREAK
Section on PDE5- inhibitors: Potential benefits to the CV System; potential safety concerns when dietary supplements are adulterated with PDE-5 inhibitors; and mechanisms Moderator:
Arthur L. Burnett MD
1:05 PM - 1:20 PM “Potential cardiovascular benefits in general population of men with ED, in diabetics, in men with other risk factors. Are PDE-5 inhibitors cardioprotective?” Robert A. Kloner MD, PhD
1:20 PM - 1:35 PM “Mechanisms of action of PDE-5 inhibitors- summary of findings from basic science research on vascular and cellular mechanisms in ED. Potential impact of PDE-5 inhibition on these systems.” Arthur L. Burnett MD
Section on Therapies for ED Beyond PDE-5 Inhibitors Moderator:
Martin Miner MD
1:35 PM - 1:50 PM “Restorative Therapy for ED: Stem cells, Shock Waves, and Platelet Rich Plasma” Tom Lue MD
1:50 PM - 2:05 PM “Alternatives to PDE5- Inhibitors: Injection therapy and prostheses” John Mulhall MD
2:05 PM - 2:40 PM PANEL 3 Moderators:
Arthur L. Burnett MD
Martin Miner MD
Robert A. Kloner MD, PhD
Arthur L. Burnett MD
Tom Lue MD
John Mulhall MD
Section on Female Sexual Dysfunction Moderator:
Sharon J. Parish MD
3:00 PM - 3:15 PM “Cardiovascular safety and benefits of PDE-5 inhibition in women with female sexual dysfunction (FSD). (Summary of findings from clinical trials of PDE-5 inhibition in women). ” Irwin Goldstein MD
3:15 PM - 3:30 PM “Neurovascular mechanisms in female sexual arousal disorders and potential targets in women. (Is there a role for topical or oral PDE-5 inhibition in treating female sexual dysfunction (FSD)? ” Noel Kim PhD
3:30 PM - 3:45 PM “Status of diagnostic and treatment guidelines for FSD in women.” Sharon J. Parish MD
3:45 PM - 4:15 PM PANEL 4 Moderators:
Sharon J. Parish MD
Ira Sharlip MD
Irwin Goldstein MD
Noel Kim PhD
Sharon J. Parish MD
4:15 PM - 4:30 PM Closing Remarks and Summary Robert A. Kloner MD PhD
Raymond Rosen PhD